For research use only. Not for therapeutic Use.
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine[1].
Lorvotuzumab mertansine (IMGN901) is an ADC that links a potent anti-mitotic (DM1) via a disulfide linker to CD56 targeting antibodies (Lorvotuzumab). Lorvotuzumab mertansine against Wilms tumor, rhabdomyosarcoma, and neuroblastoma[1].
| Catalog Number | I042221 |
| CAS Number | 339306-30-8 |
| Purity | ≥95% |
| Reference | [1]. James I Geller, et al. ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children’s Oncology Group study. Cancer. 2020 Dec 15;126(24):5303-5310. |
